Ratio de margen de beneficio operativo
desde 2005
Cálculo
Illumina Inc., ratio de margen de beneficio operativo, tendencias a largo plazocálculo
| Ratio de margen de beneficio operativo | = | 100 | × | Ingresos (pérdidas) de las operaciones1 | ÷ | Ingresos1 | |
|---|---|---|---|---|---|---|---|
| 31 dic. 2020 | 17.91% | = | 100 | × | 580 | ÷ | 3,239 |
| 29 dic. 2019 | 27.80% | = | 100 | × | 985 | ÷ | 3,543 |
| 30 dic. 2018 | 26.49% | = | 100 | × | 883 | ÷ | 3,333 |
| 31 dic. 2017 | 22.02% | = | 100 | × | 606 | ÷ | 2,752 |
| 1 ene. 2017 | 24.48% | = | 100 | × | 587 | ÷ | 2,398 |
| 3 ene. 2016 | 27.61% | = | 100 | × | 613 | ÷ | 2,220 |
| 28 dic. 2014 | 27.65% | = | 100 | × | 515 | ÷ | 1,861 |
| 29 dic. 2013 | 9.44% | = | 100 | × | 134 | ÷ | 1,421 |
| 30 dic. 2012 | 17.48% | = | 100 | × | 201 | ÷ | 1,149 |
| 1 ene. 2012 | 18.90% | = | 100 | × | 199 | ÷ | 1,056 |
| 2 ene. 2011 | 23.45% | = | 100 | × | 212 | ÷ | 903 |
| 3 ene. 2010 | 18.85% | = | 100 | × | 126 | ÷ | 666 |
| 28 dic. 2008 | 14.04% | = | 100 | × | 80 | ÷ | 573 |
| 30 dic. 2007 | -82.12% | = | 100 | × | (301) | ÷ | 367 |
| 31 dic. 2006 | 20.48% | = | 100 | × | 38 | ÷ | 185 |
| 1 ene. 2006 | -29.18% | = | 100 | × | (21) | ÷ | 74 |
Basado en informes: 10-K (fecha de reporte: 2020-12-31), 10-K (fecha de reporte: 2019-12-29), 10-K (fecha de reporte: 2018-12-30), 10-K (fecha de reporte: 2017-12-31), 10-K (fecha de reporte: 2017-01-01), 10-K (fecha de reporte: 2016-01-03), 10-K (fecha de reporte: 2014-12-28), 10-K (fecha de reporte: 2013-12-29), 10-K (fecha de reporte: 2012-12-30), 10-K (fecha de reporte: 2012-01-01), 10-K (fecha de reporte: 2011-01-02), 10-K (fecha de reporte: 2010-01-03), 10-K (fecha de reporte: 2008-12-28), 10-K (fecha de reporte: 2007-12-30), 10-K (fecha de reporte: 2006-12-31), 10-K (fecha de reporte: 2006-01-01).
1 US$ en millones
Comparación con los competidores
Illumina Inc., ratio de margen de beneficio operativo, tendencias a largo plazo, comparación con los competidores
| Illumina Inc. | AbbVie Inc. | Amgen Inc. | Gilead Sciences Inc. | Moderna Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|
| 31 dic. 2020 | 17.91% | 24.81% | 37.70% | 16.72% | -381.82% | 42.09% | 24.19% |
| 29 dic. 2019 | 27.80% | 39.03% | 43.57% | 19.38% | — | 28.10% | 17.99% |
| 30 dic. 2018 | 26.49% | 19.49% | 45.55% | 37.83% | — | 37.77% | 15.53% |
| 31 dic. 2017 | 22.02% | 33.99% | 45.76% | 55.04% | — | 35.41% | 14.19% |
| 1 ene. 2017 | 24.48% | 36.60% | 44.74% | 58.87% | — | 27.38% | 13.40% |
| 3 ene. 2016 | 27.61% | 32.97% | 40.44% | 69.03% | — | 30.51% | 13.77% |
| 28 dic. 2014 | 27.65% | 17.09% | 32.03% | 62.37% | — | 29.74% | 14.82% |
| 29 dic. 2013 | 9.44% | 30.14% | 32.25% | 41.87% | — | 36.11% | 12.30% |
| 30 dic. 2012 | 17.48% | 31.65% | 33.52% | 42.67% | — | 33.20% | 11.85% |
| 1 ene. 2012 | 18.90% | — | 28.19% | 46.77% | — | -46.02% | 10.62% |
| 2 ene. 2011 | 23.45% | — | 37.82% | 53.62% | — | -21.23% | 11.72% |
| 3 ene. 2010 | 18.85% | — | 38.37% | 54.55% | — | -19.54% | 10.38% |
| 28 dic. 2008 | 14.04% | — | 35.50% | 52.68% | — | -37.67% | 11.71% |
| 30 dic. 2007 | -82.12% | — | 27.81% | 57.98% | — | -91.55% | 10.00% |
| 31 dic. 2006 | 20.48% | — | 27.71% | -29.32% | — | -169.68% | 6.38% |
| 1 ene. 2006 | -29.18% | — | 40.33% | 61.41% | — | -187.97% | 10.01% |
Basado en informes: 10-K (fecha de reporte: 2020-12-31), 10-K (fecha de reporte: 2019-12-29), 10-K (fecha de reporte: 2018-12-30), 10-K (fecha de reporte: 2017-12-31), 10-K (fecha de reporte: 2017-01-01), 10-K (fecha de reporte: 2016-01-03), 10-K (fecha de reporte: 2014-12-28), 10-K (fecha de reporte: 2013-12-29), 10-K (fecha de reporte: 2012-12-30), 10-K (fecha de reporte: 2012-01-01), 10-K (fecha de reporte: 2011-01-02), 10-K (fecha de reporte: 2010-01-03), 10-K (fecha de reporte: 2008-12-28), 10-K (fecha de reporte: 2007-12-30), 10-K (fecha de reporte: 2006-12-31), 10-K (fecha de reporte: 2006-01-01).